Royalty Pharma plc (RPRX) Q4 FY25 Earnings Call

Strong recurring growth and pipeline optionality continue, but 2026 guidance incorporates product exclusivity losses and lower milestones.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-15
Length58 minutes
EPS$1.46
EPS consensus$1.33
Revenue$622.0M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All RPRX earnings ยท Back to RPRX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.